{"id":"das181","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAS181 consists of the extracellular domain of human dipeptidyl peptidase 4 (DPP4) fused to the Fc region of human IgG1. It acts as a decoy receptor that competitively inhibits viral attachment and entry into host cells. This mechanism is particularly effective against viruses that use DPP4 as a cellular entry point, such as MERS-CoV and other respiratory viruses.","oneSentence":"DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:46.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (SARS-CoV-2 infection)"},{"name":"MERS-CoV infection"}]},"trialDetails":[{"nctId":"NCT03808922","phase":"PHASE3","title":"Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study","status":"RECRUITING","sponsor":"Ansun Biopharma, Inc.","startDate":"2019-05-23","conditions":"Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised","enrollment":274},{"nctId":"NCT04354389","phase":"PHASE2, PHASE3","title":"DAS181 for STOP COVID-19","status":"WITHDRAWN","sponsor":"Ansun Biopharma, Inc.","startDate":"2020-07-25","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04298060","phase":"PHASE2","title":"DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","status":"UNKNOWN","sponsor":"Ansun Biopharma, Inc.","startDate":"2020-07","conditions":"Influenza Infection, SAD-RV Infection and COVID-19","enrollment":280},{"nctId":"NCT04460547","phase":"","title":"Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic","status":"UNKNOWN","sponsor":"Qassim University","startDate":"2020-07-25","conditions":"COVID-19","enrollment":200},{"nctId":"NCT04324489","phase":"NA","title":"DAS181 for Severe COVID-19: Compassionate Use","status":"COMPLETED","sponsor":"Renmin Hospital of Wuhan University","startDate":"2020-03-06","conditions":"COVID-19","enrollment":4},{"nctId":"NCT01441024","phase":"PHASE2","title":"DAS181 in Patients With Parainfluenza","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-07-14","conditions":"Parainfluenza Infection","enrollment":""},{"nctId":"NCT00876161","phase":"PHASE1","title":"DAS181 Single Dose Escalation Study in Healthy Adults","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2009-05-18","conditions":"Healthy","enrollment":45},{"nctId":"NCT01740063","phase":"PHASE2","title":"Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2012-11","conditions":"Influenza","enrollment":423},{"nctId":"NCT01113034","phase":"PHASE1","title":"A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2010-07","conditions":"Asthma, Bronchiectasis","enrollment":11},{"nctId":"NCT01644877","phase":"PHASE2","title":"A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2014-03","conditions":"Parainfluenza","enrollment":111},{"nctId":"NCT01924793","phase":"PHASE2","title":"An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2013-08","conditions":"Parainfluenza","enrollment":23},{"nctId":"NCT01651494","phase":"PHASE1","title":"Influenza Antiviral DAS-181-F04 in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-08-12","conditions":"Influenza","enrollment":9},{"nctId":"NCT01037205","phase":"PHASE2","title":"Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2009-12","conditions":"Influenza","enrollment":264},{"nctId":"NCT01173224","phase":"PHASE1","title":"Influenza Antiviral DAS181-F03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-11","conditions":"Influenza","enrollment":18},{"nctId":"NCT00527865","phase":"PHASE1","title":"Single Dose Escalating Study of DAS181 in Adults","status":"COMPLETED","sponsor":"Ansun Biopharma, Inc.","startDate":"2007-10","conditions":"Influenza","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DAS181","genericName":"DAS181","companyName":"Ansun Biopharma, Inc.","companyId":"ansun-biopharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAS181 is a recombinant fusion protein that blocks viral entry by binding to the DPP4 receptor on host cells, preventing respiratory viruses from infecting cells. Used for COVID-19 (SARS-CoV-2 infection), MERS-CoV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}